Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
epcoritamab
- Development stage
- Approved
- Lead developer
- AbbVie
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Epcoritamab is a humanized bispecific monoclonal antibody that functions as a T-cell engager. It targets CD20 on B cells and CD3 on T cells, bringing these two cell types into close proximity to facilitate T-cell–mediated killing of malignant B cells. Epcoritamab is administered subcutaneously and is approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and follicular lymphoma after at least two prior lines of systemic therapy. The drug was co-developed by Genmab and AbbVie. Its mechanism involves redirecting and activating T cells to kill CD20-expressing malignant cells through selective cytotoxic activity[1][2][5][6][7].
- Brand names
- Epkinly
- Other names
- epcoritamab-bysp
02
Targets
CD20 (B-lymphocyte antigen CD20)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on epcoritamab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on epcoritamab.